Hematologic Malignancies: Polycythemia Vera | Special Reports

Gaining More Benefit from Ruxolitinib for Patients With Polycythemia Vera, Other MPNs

September 28, 2016

Clinical Articles

Since its approval 5 years ago, ruxolitinib (Jakafi) continues to drastically change the treatment landscape and quality of life of patients with myeloproliferative neoplasms (MPNs), including a subset of patients with the bone marrow neoplasm, polycythemia vera (PV).

Management of ET, PV Requires 2 Distinct Approaches

September 28, 2016

Clinical Articles

Distinguishing between polycythemia vera (PV) and essential thrombocythemia (ET) is key for the effective treatment of both diseases, said Heinz Gisslinger, MD, of the Medical University of Vienna.

Ruxolitinib Beats Out Best Available Therapy in Polycythemia Vera

September 27, 2016

Clinical Articles

Follow up at 80 weeks to the open-label phase III RESPONSE trial confirmed the benefit of ruxolitinib over best available therapy (BAT) in the treatment of patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea.

Significant Developments in Treating PV

September 27, 2016

Clinical Articles

Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, discusses the most recent developments in diagnosing polycythemia vera.